An experimental Alzheimer’s drug shows some promise as researchers hunt new approaches

Researchers are exploring new approaches to treating Alzheimer's disease, and an experimental drug has shown some promise. The drug, called diranersen, targets a brain protein called tau, which is associated with the disease.

Brain scan images have illustrated the drug's potential to lower tau levels. This is a different approach than current treatments, which focus on another protein called amyloid.

Further details on the study, including its methodology and outcomes, are available from the source. The study involved around 400 participants and was conducted by Biogen, the company developing the experimental drug.